What is Isotretinoin?
Isotretinoin (13-cis-retinoic acid), commonly known by its former brand name Accutane, is a powerful oral retinoid medication used primarily for the treatment of severe, recalcitrant nodular acne that has not responded to conventional therapies including oral antibiotics. First approved by the FDA in 1982, isotretinoin remains the most effective treatment for severe acne and is the only medication that can produce long-term remission or cure of acne in most patients.
Isotretinoin is a synthetic derivative of vitamin A (retinol). It is available in capsule form in various strengths, typically 10 mg, 20 mg, 30 mg, and 40 mg. Brand names currently available include Absorica, Amnesteem, Claravis, Myorisan, and Zenatane. The original brand Accutane was discontinued by its manufacturer in 2009 due to declining market share from generic competition, but the drug remains widely available under generic names.
Due to its significant side effect profile and teratogenic potential, isotretinoin is reserved for cases where other treatments have failed. Typical candidates have tried and failed at least one course of oral antibiotics (such as doxycycline or minocycline) combined with topical retinoids and benzoyl peroxide. Exceptions may be made for patients with severe scarring acne, significant psychological distress from acne, or acne fulminans, where early initiation of isotretinoin may be appropriate.
Mechanism of Action
Isotretinoin's efficacy in acne treatment stems from its action on all four major factors involved in acne pathogenesis. No other single medication addresses all four simultaneously, which explains isotretinoin's unique ability to produce lasting remission:
- Sebum reduction: Isotretinoin dramatically reduces sebaceous gland size and sebum production, often by 70 to 90 percent during treatment. Sebaceous glands may shrink to a fraction of their original size. This effect partially reverses after treatment ends, but sebum production typically remains lower than pre-treatment levels for years, which is believed to contribute to the lasting remission.
- Anti-keratinization: The drug normalizes follicular keratinization, reducing the formation of microcomedones (the precursor to all acne lesions). By preventing the abnormal shedding and clumping of skin cells within the hair follicle, isotretinoin prevents pore blockages that initiate the acne cascade.
- Anti-inflammatory: Isotretinoin has direct anti-inflammatory effects, reducing the production of inflammatory mediators and inhibiting the migration of neutrophils and other immune cells to acne lesions. This helps resolve existing inflammatory nodules and cysts.
- Indirect antibacterial effect: By reducing sebum production, isotretinoin creates an environment that is less favorable for Cutibacterium acnes (formerly Propionibacterium acnes), the bacterium implicated in acne inflammation. C. acnes populations decline significantly during treatment, though this is a secondary rather than direct antibacterial effect.
Dosing Protocols
Isotretinoin dosing has evolved significantly since the drug's introduction. The two key principles of modern dosing are: (1) achieving a sufficient cumulative dose to minimize relapse risk, and (2) adjusting the daily dose to balance efficacy against side effect tolerance.
| Protocol | Daily Dose | Duration | Notes |
|---|---|---|---|
| Standard dose | 0.5–1.0 mg/kg/day | 4–6 months | Most common approach; dose titrated based on tolerance |
| Low dose | 0.25–0.5 mg/kg/day | 6–9 months | Fewer side effects; similar efficacy; longer duration |
| High dose | 1.0–2.0 mg/kg/day | 3–4 months | Faster results; more side effects; used in severe cases |
| Microdose / Pulse | 5–20 mg/day | 6–12+ months | Emerging approach for mild-moderate or maintenance |
Most dermatologists begin treatment at a lower dose (0.5 mg/kg/day or about 20 to 40 mg/day for an average adult) for the first month to assess tolerance and minimize the initial "purging" period. The dose is then increased to 0.5 to 1.0 mg/kg/day based on tolerability. Isotretinoin should be taken with a fatty meal, as absorption increases by approximately 2-fold when taken with high-fat food (at least 20 grams of fat per meal).
The 120–150 mg/kg Cumulative Dose Target
The concept of a cumulative dose target is central to isotretinoin therapy. Research has consistently shown that achieving a total cumulative dose of at least 120 mg/kg is associated with significantly lower relapse rates compared to lower cumulative doses. This target was established through multiple clinical studies demonstrating that patients who received higher total doses had better long-term outcomes.
The 120 mg/kg target is considered the minimum for optimal outcomes. Some dermatologists prefer a higher target of 150 mg/kg, particularly for patients with severe acne, truncal acne, or those at higher risk of relapse (such as younger patients or those with a strong family history). Studies suggest that relapse rates decrease further at cumulative doses of 150 mg/kg, with rates falling from approximately 20 to 30 percent at 120 mg/kg to 10 to 20 percent at 150 mg/kg.
The daily dose in mg/kg affects how quickly the cumulative target is reached but does not significantly affect the final outcome, provided the total cumulative dose is achieved. This means that a patient taking 0.5 mg/kg/day for 8 months will have similar long-term results to one taking 1.0 mg/kg/day for 4 months, as long as both reach the same cumulative dose.
Side Effects
Isotretinoin's side effects are significant and dose-dependent. Most are related to its vitamin A-like activity and its effects on mucous membranes, lipid metabolism, and cell differentiation. While most side effects are reversible upon discontinuation, some require close monitoring:
- Dry lips (cheilitis): Occurs in virtually 100% of patients and is often considered an indicator of compliance. Persistent application of emollient lip balm is essential. Severity is dose-dependent.
- Dry skin and mucous membranes: Generalized skin dryness, dry eyes (which may preclude contact lens use), dry nose (sometimes with nosebleeds), and dry mouth are very common. Moisturizers, artificial tears, and saline nasal spray help manage these effects.
- Musculoskeletal pain: Myalgia (muscle pain) and arthralgia (joint pain) occur in approximately 15 to 30 percent of patients, particularly those engaged in vigorous physical activity. Some patients may need to reduce exercise intensity during treatment.
- Elevated lipids: Isotretinoin commonly raises triglycerides and, to a lesser extent, cholesterol. Triglyceride levels above 500 mg/dL increase the risk of pancreatitis and require dose reduction or discontinuation. Fasting lipid panels are checked regularly during treatment.
- Elevated liver enzymes: Transaminase elevations occur in approximately 10 to 15 percent of patients. Levels are usually mildly elevated and rarely clinically significant, but liver function tests are monitored monthly.
- Photosensitivity: Increased susceptibility to sunburn. Patients should use broad-spectrum sunscreen (SPF 30+), wear protective clothing, and avoid prolonged sun exposure and tanning beds.
- Initial acne flare (purging): Some patients experience a temporary worsening of acne during the first 2 to 4 weeks of treatment. This is more common at higher starting doses, which is why many dermatologists begin with lower doses.
- Mood changes: The relationship between isotretinoin and depression or suicidality has been extensively debated. Large-scale epidemiological studies have not established a causal link, and some studies suggest acne improvement may actually improve mood. Nevertheless, patients should be monitored for mood changes, and any concerns should be discussed with the prescriber.
Monitoring Requirements
Safe isotretinoin therapy requires regular clinical and laboratory monitoring throughout the treatment course:
| Test | Baseline | Monthly | Purpose |
|---|---|---|---|
| Pregnancy test | Yes (2 tests) | Yes | Required by iPLEDGE for females of childbearing potential |
| Lipid panel | Yes | Yes | Monitor triglycerides and cholesterol |
| Liver function tests | Yes | Yes | Monitor for hepatotoxicity (AST, ALT) |
| CBC with differential | Yes | Optional | Rarely affected but checked at baseline |
| Clinical assessment | Yes | Yes | Acne response, side effects, mood screening |
Laboratory monitoring intervals can vary by practitioner. Some dermatologists check labs at baseline, one month, and then every other month if results are stable. Others maintain monthly monitoring throughout the course. If significant abnormalities are detected (triglycerides above 300 mg/dL, liver enzymes above 2 to 3 times the upper limit of normal), the dose may be reduced or the medication temporarily discontinued until values normalize.
Pregnancy Contraindication and iPLEDGE
Isotretinoin is classified as FDA Pregnancy Category X, meaning it is absolutely contraindicated in pregnancy. Exposure during pregnancy causes a characteristic pattern of severe birth defects known as isotretinoin embryopathy, which includes craniofacial malformations (microtia, cleft palate), cardiac defects, central nervous system abnormalities, and thymic abnormalities. The risk of birth defects approaches 25 to 35 percent with any exposure during pregnancy, and miscarriage rates are also significantly elevated.
The iPLEDGE program is a mandatory FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) in the United States. All patients, prescribers, and pharmacies must be registered in iPLEDGE before isotretinoin can be prescribed or dispensed. Key requirements include:
- Female patients of childbearing potential: Must have two negative pregnancy tests before starting, use two forms of contraception simultaneously starting one month before, during, and one month after treatment, and complete monthly pregnancy tests throughout the course.
- All patients: Must sign informed consent acknowledging the risks, must pick up prescriptions within a 7-day window, and prescriptions are limited to a 30-day supply.
- Prescribers: Must be registered, must verify patient compliance and pregnancy test results monthly, and must complete the monthly iPLEDGE confirmation before prescriptions can be filled.
Isotretinoin has a short half-life of approximately 21 hours, and is completely eliminated from the body within about one month after discontinuation. Female patients must continue contraception for one month after stopping the drug and should not donate blood for one month after the last dose (to prevent the blood being given to a pregnant woman).
Treatment Timeline Diagram
Worked Example
A 70 kg patient is prescribed 40 mg/day of isotretinoin with a standard target of 120 mg/kg:
At 40 mg/day, the patient would take 2 capsules of 20 mg each daily with a fatty meal. The treatment would last approximately 7 months. If the patient is in month 3, they have completed about 3,600 mg (43% of the total), with approximately 4 months remaining.
Frequently Asked Questions
How long does isotretinoin treatment last?
Treatment duration depends on the daily dose and body weight. Most courses last 5 to 7 months when using a standard daily dose of 0.5 to 1.0 mg/kg. Low-dose protocols may extend treatment to 8 to 12 months. The goal is to reach a cumulative dose of 120 to 150 mg/kg, regardless of how long it takes. Treatment should not be stopped simply because the skin has cleared; the full cumulative dose is necessary to minimize relapse risk.
What happens if I miss a dose?
If you miss a dose, take it as soon as you remember on the same day (with food). If you do not remember until the next day, skip the missed dose and continue your regular schedule. Do not take double doses. Missing occasional doses will extend your treatment duration slightly but is not dangerous. Consistent daily dosing is preferred to reach the cumulative target efficiently.
Can I drink alcohol while on isotretinoin?
Moderate alcohol consumption (occasional light drinking) is generally considered safe for most patients, but heavy or binge drinking should be avoided. Both isotretinoin and alcohol are metabolized by the liver, and combining them increases the risk of liver enzyme elevations and triglyceride increases. Patients with baseline liver issues or elevated lipids should be particularly cautious. Discuss your alcohol use honestly with your dermatologist.
Will my acne come back after treatment?
Approximately 70 to 80 percent of patients who complete a full course at 120 mg/kg or higher experience long-term remission or cure. About 20 to 30 percent may relapse, typically within 2 years of completing treatment. Relapse is more common in younger patients (under 16), those with severe acne, patients with truncal acne, patients with polycystic ovary syndrome, and those who received a lower cumulative dose. A second course is effective and safe for those who relapse.
What is the purging phase?
The "purge" refers to an initial worsening of acne that some patients experience during the first 2 to 4 weeks of treatment. This occurs because isotretinoin accelerates cell turnover in the skin, bringing existing microcomedones to the surface as active lesions more rapidly. Not all patients experience purging, and it is more common at higher starting doses. Starting at a lower dose (20 mg/day or 0.25 to 0.5 mg/kg/day) for the first month can minimize purging.
Why must I take isotretinoin with fat?
Isotretinoin is a highly lipophilic (fat-soluble) molecule. Its absorption from the gastrointestinal tract approximately doubles when taken with a meal containing at least 20 grams of fat compared to taking it on an empty stomach. Common fatty food options include avocado, peanut butter, cheese, nuts, or a meal cooked with oil. Some newer formulations (such as Absorica) have been designed with improved absorption that is less dependent on food, but taking all isotretinoin formulations with fat remains best practice.